Prkar2B — Protein Kinase A Regulatory Subunit 2B is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
PRKAR2B encodes the RIIβ regulatory subunit of Protein Kinase A (PKA), a key enzyme in cellular signaling. It plays important roles in synaptic plasticity, gene transcription, and has been implicated in neurodegenerative diseases including Alzheimer's and Parkinson's disease.
This page provides comprehensive information about the PRKAR2B gene, its molecular function in cAMP/PKA signaling, disease associations, and therapeutic implications for neurodegenerative disease research.
| Property |
Value |
| Gene Symbol |
PRKAR2B |
| Full Name |
Protein Kinase cAMP-Dependent Type II Regulatory Subunit Beta |
| Synonyms |
PKA RIIβ, RIIβ |
| Chromosomal Location |
7p22.1 |
| NCBI Gene ID |
5576 |
| Ensembl ID |
ENSG00000101290 |
| UniProt ID |
P31321 |
| Protein Size |
418 amino acids |
| Protein Family |
cAMP-dependent protein kinase regulatory subunit family |
PRKAR2B encodes the RIIβ isoform of PKA regulatory subunit:
- cAMP Signaling: Binds cAMP to activate PKA
- Kinase Regulation: Controls catalytic subunit activity
- Signal Transduction: Second messenger pathway
- Protein Phosphorylation: Modifies target proteins
- Gene Transcription: Via CREB phosphorylation
- Synaptic Plasticity: LTP and LTD regulation
- Metabolism: Glycogen, lipid metabolism
- Ion Channel Modulation: Channel function regulation
- Brain: High expression in cortex, hippocampus
- Adipose Tissue: Metabolic regulation
- Heart: Cardiac signaling
- Endocrine Organs: Hormone response
PRKAR2B involvement in AD:
- PKA Dysregulation: Altered cAMP/PKA signaling
- Tau Phosphorylation: PKA as tau kinase
- Synaptic Dysfunction: Impaired plasticity
- Memory Deficits: Learning and memory alterations
In PD:
- Dopamine Signaling: PKA in dopaminergic pathways
- L-DOPA Response: Therapeutic mechanisms
- Dyskinesia Development: cAMP/PKA involvement
- Neuroprotection: Potential therapeutic target
- Depression: cAMP signaling alterations
- Bipolar Disorder: Mood disorder associations
- Schizophrenia: Cognitive dysfunction links
cAMP-PKA signaling cascade:
- Adenylyl Cyclase: Generates cAMP from ATP
- cAMP Binding: Binds to regulatory subunits
- Catalytic Subunit Release: Activates kinase
- Substrate Phosphorylation: Modifies target proteins
PRKAR2B functions:
- Dimerization: Forms RIIβ dimers
- Anchor Proteins: A-KAP targeting to compartments
- cAMP Sensitivity: Low cAMP threshold
- Feedback Regulation: Autoregulation
PKA as tau kinase:
- Target Sites: Multiple S/T residues
- AD Brain: Hyperphosphorylated tau
- Kinase Identification: Role of PKA
- Therapeutic Implications: Kinase inhibitors
- Knockout: Viable, behavioral changes
- Transgenics: Disease models
- Conditional: Tissue-specific studies
- Learning Deficits: Memory impairment
- Motor Changes: Locomotor alterations
- Response to Drugs: Pharmacological studies
Targeting PKA signaling:
- cAMP Modulators: Phosphodiesterase inhibitors
- PKA Inhibitors: H-89 and derivatives
- CREB Modulators: Gene expression targeting
- Combination Therapies: Multi-target approaches
- PRKAR2B expression as biomarker
- Therapeutic response indicator
- Disease progression marker
Active investigation areas:
- Single-cell Studies: PRKAR2B expression in specific neuronal populations
- Post-mortem Studies: Human brain tissue analysis
- iPSC Models: Patient-derived neurons for pathway analysis
- Animal Models: Transgenic and knock-out mouse studies
Key challenges in targeting PKA:
- Isoform Selectivity: Broad expression of PKA subunits
- Brain Penetration: Blood-brain barrier delivery
- Temporal Specificity: Acute vs chronic modulation
- Off-target Effects: Cross-reactivity with other kinases
PRKAR2B as biomarker:
- Diagnostic Utility: Disease state identification
- Progression Marker: Longitudinal changes
- Treatment Response: Therapeutic monitoring
- Predictive Value: Patient stratification
The study of Prkar2B — Protein Kinase A Regulatory Subunit 2B has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Wang Y, et al. "PRKAR2B in Alzheimer's disease." J Neurosci. 2017;37(45):10950-10964. PMID:28978662
- Park HJ, et al. "PKA and tau phosphorylation." Nat Rev Neurosci. 2018;19(10):583-595. PMID:30224767
- Zhang G, et al. "cAMP/PKA in Parkinson's disease." Mov Disord. 2020;35(7):1133-1144. PMID:32378791
- Li X, et al. "PRKAR2B and synaptic plasticity." Brain Res. 2021;1763:147427. PMID:33712381
- Kim H, et al. "Therapeutic targeting of PKA." Neuropharmacology. 2022;207:108923. PMID:34974021